0001193125-23-274500.txt : 20231109 0001193125-23-274500.hdr.sgml : 20231109 20231109160801 ACCESSION NUMBER: 0001193125-23-274500 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Akili, Inc. CENTRAL INDEX KEY: 0001850266 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 981586159 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40558 FILM NUMBER: 231392397 BUSINESS ADDRESS: STREET 1: 125 BROAD STREET, 5TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-456-0597 MAIL ADDRESS: STREET 1: 125 BROAD STREET, 5TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: Social Capital Suvretta Holdings Corp. I DATE OF NAME CHANGE: 20210310 8-K 1 d595423d8k.htm 8-K 8-K
NASDAQ false 0001850266 0001850266 2023-11-09 2023-11-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

November 9, 2023 (November 9, 2023)

 

 

Akili, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40558   92-3654772

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

125 Broad Street, Fifth Floor,

Boston, MA

   02110
(Address of Principal Executive Offices)   (Zip Code)

(617) 456-0597

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common stock, par value $0.0001 per share   AKLI   Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On November 9, 2023, Akili, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023. A copy of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. This Exhibit 99.1 shall be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall be incorporated by reference in all appropriate filings under the Securities Act of 1933, as amended, except for the second paragraph of Exhibit 99.1 and the full text in the subsections (including the bullets and sub-bullets) under the captions “Non-GAAP Total Operating Expenses” and “Gross Margins,” each of which are included under the section header “Reiterating Financial Guidance,” each of which shall be “furnished” and not “filed.”

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

No.

    Description of Exhibit
99.1    Press Release issued by Akili, Inc. on November 9, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Akili, Inc.
By:  

/s/ Santosh Shanbhag

Name:   Santosh Shanbhag
Title:   Chief Financial Officer

Date: November 9, 2023

EX-99.1 2 d595423dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Akili Reports Third Quarter 2023 Financial Results and Provides Business Update

Reports third quarter total revenues of $702 thousand, representing more than 5x growth over

the second quarter of 2023, and positive gross margins of ~60% in the quarter

Company has filed EndeavorOTC with FDA as an over-the-counter treatment for adults with ADHD

BOSTON, Mass. –November 9, 2023– Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended September 30, 2023, and provided an update on business progress.

“We are pleased with early results of our previously-announced strategic shift from a prescription to a non-prescription business model focused on EndeavorOTC. It’s clear that there is strong demand from individuals struggling with ADHD, and that they are actively seeking new treatment options. Our direct-to-consumer strategy removes accessibility barriers to this clinically-validated treatment,” said Matt Franklin, CEO of Akili. “We’ve submitted EndeavorOTC for FDA review and authorization as an over-the-counter medical product in the adult ADHD market, and anticipate that these business model changes combined with our new direct-to-consumer marketing efforts will accelerate the path to profitability.”

Business Update

 

  •  

On October 30, 2023, Akili submitted a 510(k) application to FDA for EndeavorOTC as an over-the-counter treatment for adults with ADHD. The submission was received by FDA on October 30, 2023 and is currently undergoing technical review by FDA.

 

  ○ 

Pursuant to FDA guidance, Akili is continuing to make EndeavorOTC available over-the-counter, without a prescription, while its submission to FDA is under review.

 

  •  

Akili also continues to seek FDA authorization for its EndeavorRx label expansion to include adolescents ages 13-17 with ADHD; this filing was accepted by FDA in May 2023 and remains under review.

 

  ○ 

As disclosed in September 2023, Akili plans to pursue regulatory approval for over-the-counter labeling of both of its treatment products and is planning to submit data to FDA in 2024 to potentially convert its EndeavorRx product to over-the-counter labeling.

 

  •  

With respect to Akili’s ongoing partnership with Shionogi, the Phase 3 study for pediatric ADHD in Japan, which includes both a randomized phase and a longer term follow-up phase, is expected to be complete by the end of the first quarter of 2024. Shionogi plans to submit the results of this trial for regulatory approval to Japan’s Pharmaceuticals and Medical Devices Agency in 2024.

 

  •  

Effective October 16, 2023, Akili mutually agreed with TALi Digital Limited to terminate the parties’ license, development and commercialization agreement and Akili plans to focus its resources on expanding adoption of its adult non-prescription product.

 

  •  

EndeavorOTC metrics in the third quarter of 2023:

 

  ○ 

176,559 first-time app downloads in the period

 

  ○ 

7,535 active subscribers, defined as total users with a paid subscription in the period

 

  ○ 

$553 thousand in revenues and $533 thousand in billings (a non-GAAP financial measure defined as EndeavorOTC revenues plus the change in deferred revenue)

 

  ○ 

$93 average revenue per paying user in the period (ARPU), defined as revenues divided by subscribers who paid within the period

Third Quarter 2023 Financial Highlights

 

  •  

Cash position: Cash, cash equivalents, and short-term investments as of September 30, 2023 were $86.3 million.

 

  •  

Revenues: Total revenues for the third quarter of 2023 were $702 thousand compared to $114 thousand for the second quarter of 2023, driven by the continued growth of EndeavorOTC in the adult ADHD market.

 

  •  

Total billings: Total billings, a non-GAAP financial measure defined as revenues plus the change in deferred revenue, were $699 thousand for the third quarter of 2023, compared to $170 thousand for the second quarter of 2023.

 

  •  

Total Operating Expenses: GAAP total operating expenses were $18.8 million for the third quarter of 2023, compared to $15.3 million for the second quarter of 2023, driven by increases in EndeavorOTC marketing-related expenses and severance-related charges associated with the headcount reduction announced in September 2023. Non-GAAP total operating expenses were $14.7 million for the third quarter of 2023, compared to $13.1 million for the second quarter of 2023, driven by an increase in EndeavorOTC marketing-related expenses partially offset by the savings associated with the headcount reduction announced in September 2023.

 

  •  

Gross Margins: Total gross margins were ~60% in the third quarter of 2023 compared to ~-32% in the second quarter of 2023, driven by the impact of the June 2023 launch of EndeavorOTC in the adult ADHD market.

 

  •  

Net income (loss): GAAP net loss was $15.9 million for the third quarter of 2023, compared to a GAAP net loss of $11.8 million for the second quarter of 2023. Non-GAAP net loss was $13.9 million for the third quarter of 2023, compared to a non-GAAP net loss of $12.6 million for the second quarter of 2023.

Reiterating Financial Guidance

 

  •  

Non-GAAP Total Operating Expenses

  ○ 

2023 Non-GAAP total operating expenses expected to be between $55 million and $60 million, which excludes stock-based compensation expense, an

  impairment loss on certain assets associated with our sublease and severance and termination-related costs associated with reductions to our workforce

 

  ○ 

2024 Non-GAAP total operating expenses expected to be between $42 million and $47 million, which excludes stock-based compensation expense

 

  •  

Cash Runway

 

  ○ 

Cash, cash equivalents, and short-term investments are expected to be sufficient to fund current and planned operations into the second half of 2025

 

  •  

Gross Margins

 

  ○ 

By late 2025, non-prescription business model expected to operate at 60-70% gross margins

For additional information, please see the tables below, which include a reconciliation of the historical non-GAAP financial measures to GAAP financial measures.

Webcast and Conference Call

Akili will host a conference call and webcast today, Thursday, November 9, 2023, at 4:30 p.m. ET. A live audio webcast of the conference call and presentation will be available at www.akiliinteractive.com under Investor Relations, Events & Presentations, along with slides that may be referenced during the call. An archived version of the webcast will be available on the Company’s website following the event.

To access the call, dial 888-259-6580 (toll-free) or +1 206-962-3782 (international) and reference “Akili Third Quarter 2023 Earnings.”

Non-GAAP Financial Measures

In addition to financial information prepared and presented in accordance with generally accepted accounting principles in the United States (GAAP), this press release includes the following non-GAAP financial measures: total billings on a historical basis, non-GAAP total operating expenses on a historical basis, non-GAAP net loss on a historical basis and non-GAAP total operating expenses on a projected basis. Akili derives these non-GAAP financial measures by excluding or adjusting certain expenses and other items from the respective GAAP financial measure that is most directly comparable to each non-GAAP financial measure. Specifically, total billings is defined as revenues plus the change in deferred revenue during the period; 2022 non-GAAP total operating expenses on a historical basis excludes stock-based compensation expense and transaction costs allocated to earn-out shares; 2023 non-GAAP total operating expenses on a historical basis excludes stock-based compensation expense, an impairment loss on certain assets associated with our sublease and severance and termination-related costs associated with the workforce reductions during the year, and 2023 non-GAAP total operating expenses on a projected basis excludes stock-based compensation expense, an impairment loss on certain assets associated with our sublease and severance and termination-

related costs associated with the workforce reductions during the year; 2024 non-GAAP total operating expenses on a projected basis excludes stock-based compensation expense; and non-GAAP net loss excludes transaction costs allocated to earn-out shares, stock-based compensation expense, an impairment loss on certain assets associated with our sublease, severance and termination-related costs associated with the workforce reductions announced during the year, and the change in estimated fair value of earn-out liabilities. Akili’s management believes that these non-GAAP financial measures are useful to both management and investors in analyzing its ongoing business and operating performance. Management does not intend the presentation of these non-GAAP financial measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP, but as a complement to provide greater transparency. In addition, these non-GAAP financial measures may differ from similarly-named measures used by other companies. A reconciliation of the historical non-GAAP financial measures to GAAP financial measures is included in the attached financial tables. However, a quantitative reconciliation of projected non-GAAP total operating expenses to projected GAAP operating expenses is not available, nor is the probable significance of such reconciling information, due to Akili’s inability to predict with reasonable certainty the amount of future stock-based compensation expense at this time.

EndeavorOTC Indication and Overview

EndeavorOTC is a digital therapeutic indicated to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined-type ADHD. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx, a prescription digital therapeutic indicated to improve attention function in children ages 8-12. EndeavorOTC is available under the U.S. Food and Drug Administration’s current Enforcement Policy for Digital Health Devices for Treating Psychiatric Disorders During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency. EndeavorOTC has not been cleared or authorized by the U.S. Food and Drug Administration for its indications. It is recommended that patients speak to their health care provider before starting EndeavorOTC treatment. No serious adverse events have been reported in any of our clinical studies. To learn more, visit EndeavorOTC.com.

EndeavorRx Indication and Overview

EndeavorRx is the first-and-only FDA-authorized treatment delivered through a video game experience. EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8 to 12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure Test of Variables of Attention (TOVA®) of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. EndeavorRx is available by prescription only. It is not intended to be used as a stand-alone therapeutic and is not a

substitution for a child’s medication. The most common side effect observed in children in EndeavorRx’s clinical trials was a feeling of frustration, as the game can be quite challenging at times. No serious adverse events were associated with its use. EndeavorRx is recommended to be used for approximately 25 minutes a day, 5 days a week, over initially at least 4 consecutive weeks, or as recommended by your child’s health care provider. To learn more about EndeavorRx, please visit EndeavorRx.com.

About Akili

Akili is pioneering the development of cognitive treatments through game-changing technologies. Akili’s approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “prepare,” “pursue,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements include, without limitation, statements in this press release related to: our use of the STARS-ADHD-Adult study data in a regulatory submission with FDA to obtain regulatory clearance for our over-the-counter product, EndeavorOTC; our expectation regarding our ability to continue to be able to market EndeavorOTC under the relevant FDA guidance; our expectation regarding our ability to use EndeavorOTC to directly and efficiently engage with adults struggling with attention issues and ADHD; our expectation regarding the potential label expansion for EndeavorRx to include adolescents ages 13-17 with ADHD; our plans to request FDA approval of the conversion of both of our products to over-the-counter labeling and to submit data to FDA in 2024; our expectations regarding our partner Shionogi’s plans and timing regarding their Phase 3 trial and regulatory submission in Japan; our expectations regarding our path to profitability; our expectations regarding our FY 2023 and FY 2024 non-GAAP total operating expenses; our expectations regarding our future gross margin percentage; our expectation that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our current and planned operations into the second half of 2025; and our expectations regarding our continued strong demand from individuals struggling with ADHD. Any forward-looking statements in this press release are based on management’s

current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: our ability to obtain and maintain over-the-counter FDA authorization for EndeavorOTC; our ability to continue to commercialize EndeavorOTC under relevant FDA guidance; our ability to obtain regulatory clearance from FDA for a label expansion for EndeavorRx and then to obtain regulatory clearance from FDA to convert our products to over-the-counter-labeling; our ability to successfully create, and navigate, a new category of medicine and to achieve broad adoption of digital therapeutics among customers and healthcare providers; our ability to continue to advance our clinical development pipeline; our ability to defend our intellectual property and satisfy various FDA and other regulatory requirements in and outside of the United States; the risk of adverse macroeconomic or political changes and a changing regulatory landscape in the highly competitive industry in which we operate; the timing and results expected from our and our partners’ clinical trials and our reliance on third parties for certain aspects of our business; our ability to accurately estimate expenses, capital requirements, and needs for additional financing; and other risks identified in our current filings and any subsequent filings made with the Securities and Exchange Commission (SEC). We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof and should not be relied upon as representing our views as of any subsequent date. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Akili, Inc.

Unaudited Condensed Consolidated Balance Sheets

 

     September 30,
2023		     June 30,
2023		     December 31,
2022		  

Assets

       

Current assets:

       

Cash and cash equivalents

      $ 73,799         $ 56,266         $ 54,097    

Restricted cash

      305         305         305    

Short-term investments

      12,482         49,576         82,034    

Accounts receivable

      442         84         41    

Prepaid expenses and other current assets

      3,608         2,493         4,565    
  

 

 

    

 

 

    

 

 

  

Total current assets

      90,636         108,724         141,042    

Property and equipment, net

      644         715         919    

Operating lease right-of-use asset

      1,753         1,929         2,596    

Prepaid expenses and other long-term assets

      109         95         —    
  

 

 

    

 

 

    

 

 

  

Total assets

      $ 93,142         $ 111,463         $ 144,557    
  

 

 

    

 

 

    

 

 

  

Liabilities and stockholders’ equity

       

Current liabilities:

       

Accounts payable

      $ 1,217         $ 1,457         $ 2,681    

Accrued expenses and other current liabilities

      3,385         3,227         5,616    

Deferred revenue

      173         176         106    

Operating lease liability

      774         791         826    

Note payable, short term

      7,500         7,500         4,375    
  

 

 

    

 

 

    

 

 

  

Total current liabilities

      13,049         13,151         13,604    

Note payable, long term

      5,209         6,965         10,442    

Operating lease liability, net of current portion

      1,928         2,122         2,485    

Corporate bond, net of bond discount

      1,999         1,943         1,834    

Earn-out liabilities

      1,841         4,297         5,513    

Other long-term liabilities

      22         22         -        
  

 

 

    

 

 

    

 

 

  

Total liabilities

      24,048         28,500         33,878    
  

 

 

    

 

 

    

 

 

  

Commitments and contingencies

       

Stockholders’ equity

       

Common stock

      8         8         8    

Additional paid-in capital

      357,720         355,738         350,980    

Accumulated deficit

      (288,634)         (272,758)         (240,288)    

Accumulated other comprehensive income (loss)

      -             (25)         (21)    
  

 

 

    

 

 

    

 

 

  

Total stockholders’ equity

      69,094         82,963         110,679    
  

 

 

    

 

 

    

 

 

  

Total liabilities and stockholders’ equity

      $ 93,142         $ 111,463         $ 144,557    
  

 

 

    

 

 

    

 

 

  

Akili, Inc.

Unaudited Condensed Consolidated Statements of Operations

 

     Three Months Ended
September 30,		      Nine Months Ended
September 30,		      Three Months
Ended
June 30,		  
     2023      2022      2023      2022      2023  

Revenues

    $                 702        $                 82        $                 929        $                 212        $ 114    

Cost of revenues

      280          123          567          316          150    
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

Gross profit (loss)

      422          (41)         362         (104)         (36)   

Operating expenses:

               

Research and development

      4,912          7,554          15,629          21,216          4,633    

Selling, general and administrative

      13,936          16,911          37,595          47,250          10,648    
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

Total operating expenses

      18,848          24,465          53,224          68,466          15,281    
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

Operating loss

      (18,426)         (24,506)         (52,862)         (68,570)         (15,317)   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

Other income, net

      2,550          77,742          4,516          77,421          3,558    
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

Net income (loss)

    $ (15,876)       $ 53,236        $ (48,346)       $ 8,851        $ (11,759)   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

Akili, Inc.

GAAP to Non-GAAP Reconciliation

 

     Three Months Ended
September 30,		      Nine Months Ended
September 30,		      Three Months Ended
June 30,		  
     2023      2022      2023      2022      2023  

GAAP Total Operating Expenses

      $ 18,848          $ 24,465          $ 53,224          $ 68,466         $ 15,281    

Transaction costs allocated to earn-out shares

      -              (3,046)         -              (3,046)         -        

Stock-based compensation

      (1,655)         (3,153)         (6,251)         (7,192)         (1,837)   

Impairment loss on sublease

      -              -              (384)         -              (384)   

Expenses related to workforce reduction

      (2,461)         -              (4,790)         -              -        
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

Non-GAAP Total Operating Expenses

      $ 14,732          $ 18,266          $ 41,799          $ 58,228          $ 13,060    
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

GAAP Net Income (Loss)

      $ (15,876)         $ 53,236          $ (48,346)         $ 8,851          $ (11,759)   

Transaction costs allocated to earn-out shares

      -              3,046          -              3,046          -        

Stock-based compensation

      1,655          3,153          6,251          7,192          1,837    

Impairment loss on sublease

      -              -              384          -              384    

Expenses related to workforce reduction

      2,461          -              4,790          -              -        

Change in estimated fair value for earnout liabilities

      (2,128)         (77,892)         (3,182)         (77,892)         (3,067)   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

Non-GAAP Net Loss

      $ (13,888)         $ (18,457)         $ (40,103)         $ (58,803)         $ (12,605)   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

Total Revenues

      $ 702          $ 82        $ 929          $ 212          $ 114    

Deferred revenue, end of period

      173          109          173          109          176    

Deferred revenue, beginning of period

      (176)         (109)         (106)         (96)         (120)   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

Total Billings

      $ 699          $ 82          $ 996          $ 225          $ 170    
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

EndeavorOTC Revenues

      $ 553          $ -              $ 558          $ -              $ 5    

Deferred revenue, end of period

      -              -              -              -              20    

Deferred revenue, beginning of period

      (20)         -              -              -              -        
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

EndeavorOTC Billings

      $ 533          $ -              $ 558          $ -              $ 25    
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

Investor Contact:

Santosh Shanbhag

Chief Financial Officer

InvestorRelations@akiliinteractive.com

Media Contact:

Caty Reid

VP, Marketing & Communications

PR@akiliinteractive.com

###

EX-101.SCH 3 akli-20231109.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 akli-20231109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 akli-20231109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 09, 2023
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001850266
Document Type 8-K
Document Period End Date Nov. 09, 2023
Entity Registrant Name Akili, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-40558
Entity Tax Identification Number 92-3654772
Entity Address, Address Line One 125 Broad Street
Entity Address, Address Line Two Fifth Floor
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02110
City Area Code (617)
Local Phone Number 456-0597
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol AKLI
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 7 d595423d8k_htm.xml IDEA: XBRL DOCUMENT 0001850266 2023-11-09 2023-11-09 NASDAQ false 0001850266 8-K 2023-11-09 Akili, Inc. DE 001-40558 92-3654772 125 Broad Street Fifth Floor Boston MA 02110 (617) 456-0597 false false false false Common stock, par value $0.0001 per share AKLI true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports akli-20231109.xsd akli-20231109_lab.xml akli-20231109_pre.xml d595423d8k.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d595423d8k.htm": { "nsprefix": "akli", "nsuri": "http://www.akiliinteractive.com/20231109", "dts": { "schema": { "local": [ "akli-20231109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] }, "labelLink": { "local": [ "akli-20231109_lab.xml" ] }, "presentationLink": { "local": [ "akli-20231109_pre.xml" ] }, "inline": { "local": [ "d595423d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2022": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "report": { "R1": { "role": "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-11-09_to_2023-11-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d595423d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-11-09_to_2023-11-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d595423d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://www.akiliinteractive.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001193125-23-274500-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-274500-xbrl.zip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end